JPMorgan analyst Cory Kasimov raised his price target for bluebird bio shares to $244 after Saturday’s HGB-205 update at the European Hematology meeting. Kasimov notes that importantly, the sickle cell patient remains transfusion/hospitalization free, and his levels of "anti-sickling" hemoglobin continue to increase. LentiGlobin continues to be safe and well tolerated, he tells investors in a research note. Kasimov says his $244 price target reflects increased probabilities for success in sickle cell disease and beta Thalassemia. He keeps an Overweight rating on bluebird. The stock is trading up $11.85 to $192.66 in the pre-market.